Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4
Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and raises the price target from $3 to $4.
Read original at benzingaStocks · News reference
GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.09 per share from the same period last year.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:08 PM
- Checked
- Aug 5, 2026, 8:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.
Read original at benzingaCitigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.
Read original at benzingaTD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.
Read original at benzinga